Targeting the MAPK and PI3K pathways in combination with PD1 blockade in melanoma

Immunotherapy of advanced melanoma with CTLA-4 or PD-1/PD-L1 checkpoint blockade induces in a proportion of patients long durable responses. In contrast, targeting the MAPK-pathway by selective BRAF and MEK inhibitors induces high response rates, but most patients relapse. Combining targeted therapy...

Descripción completa

Detalles Bibliográficos
Autores principales: Deken, Marcel A., Gadiot, Jules, Jordanova, Ekaterina S., Lacroix, Ruben, van Gool, Melissa, Kroon, Paula, Pineda, Cristina, Geukes Foppen, Marnix H., Scolyer, Richard, Song, Ji-Ying, Verbrugge, Inge, Hoeller, Christoph, Dummer, Reinhard, Haanen, John B. A. G., Long, Georgina V., Blank, Christian U.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2016
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5215252/
https://www.ncbi.nlm.nih.gov/pubmed/28123875
http://dx.doi.org/10.1080/2162402X.2016.1238557

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5215252/
https://www.ncbi.nlm.nih.gov/pubmed/28123875
http://dx.doi.org/10.1080/2162402X.2016.1238557

Ejemplares similares